愛污传媒

Skip to main content

Sharp rise in use of weight-loss drugs of U.S. youth

A subject's waist is measured during an obesity prevention study in Chicago on Jan. 20, 2010.  (AP Photo/M. Spencer Green, File) A subject's waist is measured during an obesity prevention study in Chicago on Jan. 20, 2010. (AP Photo/M. Spencer Green, File)
Share

A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk's weight-loss drug Wegovy last year, a powerful new tool to address record rates of pediatric obesity, according to data shared exclusively with Reuters.

In the first 10 months of 2023, 1,268 children ages 12 to 17 with an obesity diagnosis started taking Wegovy, according to U.S. insurance claims data compiled by health technology company Komodo Health.

In 2022, only 25 children were prescribed the drug, which did not receive U.S. approval for adolescent use until December of that year. A month later, the influential American Academy of Pediatrics recommended weight-loss drugs be offered to children with obesity starting at age 12.

Medicaid data obtained by Reuters from five states, including Michigan, Minnesota and Wisconsin, show a similar uptick in use of Wegovy. The overall numbers remain small, with at least 464 children across the five states being prescribed the drug since January 2022.

That does not include prescriptions bought without health insurance, or off-label use of two similar treatments for type 2 diabetes, Ozempic from Novo and Mounjaro from Eli Lilly.

Even so, they are a drop in the bucket as nearly 20% of U.S. children, or about 14.7 million, have obesity, according to federal estimates.

But the data indicate an increasing willingness among families to embrace Wegovy, the first highly effective treatment for obesity, short of surgery. Use of the weekly injection can involve great cost, with limited data on long-term risks and benefits.

"I use these medications wherever I can. Unlike with adults, where it鈥檚 like a rescue operation, we are much more likely with children and adolescents to prevent disease," said Dr. Suzanne Cuda, medical director of Alamo City Healthy Kids and Families in San Antonio, Texas. Cuda was an adviser to Novo Nordisk on pediatric obesity.

Obesity has been linked to many serious health conditions including diabetes, heart disease and cancer.

In prior years, a much smaller number of adolescents were prescribed Novo鈥檚 Saxenda, which was approved for adult weight loss in 2014 and for adolescents in 2020. Saxenda works in a similar way to curb appetite as Wegovy, but results in less weight loss on average. Both belong to a class of therapies known as GLP-1 agonists.

There were 378 adolescents prescribed Saxenda in the first 10 months of 2023, the Komodo data show. That was down from 567 patients who started to use the medication in 2022. From 2018 to 2021, 266 adolescents received new Saxenda prescriptions.

A family鈥檚 decision

Billy Small Jr. of Oakland, Calif., said he and his family were initially reluctant to put their 15-year-old son on Wegovy. They worried about side effects such as nausea, vomiting and other gastrointestinal problems, as well as potential unknown risks from long-term use.

Novo鈥檚 clinical trial of Wegovy in adolescents lasted about 18 months.

Their son, Billy Small III, was 5-foot-9 (1.75 metres) and weighed 385 pounds (176 kilograms) at the time. Their pediatrician warned that he was at increased risk of developing Type 2 diabetes and heart disease. He had already been diagnosed with asthma.

"We asked Billy how he felt about it. He just really wanted the weight to be gone," said his father.

Since starting on Wegovy in March 2023, Billy has lost about 90 pounds, or 23% of his total body weight. The drug was covered by the family鈥檚 state Medicaid plan.

Billy鈥檚 appetite diminished sharply, and he rarely experienced side effects. He started to join friends for movies and basketball games and began going to the gym with his father.

"The weight was hard on his confidence," Billy Small Jr. said of his son, now 16. "His quality of life is already 100 times better than what it was."

Both Novo and Eli Lilly are testing their weight-loss drugs in children as young as 6. Lilly's drug, tirzepatide, is only approved for adults in the U.S. under the brand name Mounjaro for type 2 diabetes and Zepbound for weight loss.

Lilly said it couldn鈥檛 comment on "future plans for tirzepatide in children or adolescents as clinical trials are still ongoing."

Novo said there are about 175 million children and adolescents with obesity worldwide, and for some, a reduced-calorie diet and increased exercise may not be enough.

Global epidemic

The U.S. is among a handful of countries trying new weight-loss drugs in youth. Any lessons learned could inform health officials elsewhere. Novo said the drug received similar approvals for youth last year in Germany, the U.K., Denmark and the United Arab Emirates.

Without insurance coverage, Wegovy can cost as much as US$1,300 per month in the U.S. Data so far show a majority of people who stop taking it regain much of the lost weight. It is not clear whether there are ways to avoid using it for a lifetime.

Komodo reviewed health insurance claims involving nearly 20 million children, or about 80% of the U.S. population aged 12 to 17. Among these patients, 2.25 million adolescents had an obesity diagnosis listed in their insurance claims during the nearly six-year period reviewed. The analysis was conducted using closed insurance claims through October 2023.

Some medical experts urge caution given a lack of evidence about how these medications may affect development.

The U.S. Preventive Services Task Force recommended intensive counselling, including behavioural therapy and nutritional education, rather than medication, for helping children who need to lose weight.

"We don't really know what these medications do in the context of the growing child," said Dr. Dan Cooper, distinguished professor of pediatrics at the University of California at Irvine.

(Reporting by Robin Respaut in Oakland and Chad Terhune in Los Angeles. Editing by Michele Gershberg and Bill Berkrot)

CTVNews.ca Top Stories

Canadian musician Jacob Hoggard has been found not guilty of sexually assaulting a young woman in northeastern Ontario eight years ago. The former Hedley frontman had pleaded not guilty to sexual assault.

Police have arrested a Toronto woman in connection with three recent homicides and investigators say that they believe two of the victims may have been 'randomly targeted.'

The body of a British Columbia mountain climber has been located and recovered after the 39-year-old man was reported missing during a solo climb on Washington state's Mount Baker earlier this week.

A teen charged with the murder of another teen on Prince Edward Island last year has pleaded guilty to a lesser charge of manslaughter.

A Saskatchewan man living in the United States has pleaded guilty to possessing child pornography after he unknowingly provided disturbing videos to an FBI agent he thought was a pedophile.

Local Spotlight

Chantal Kreviazuk is set to return to Winnipeg to mark a major milestone in her illustrious musical career.

From the beaches of Cannes to the bustling streets of New York City, a new film by a trio of Manitoba directors has toured the international film festival circuit to much pomp and circumstance.

A husband and wife have been on the road trip of a lifetime and have decided to stop in Saskatchewan for the winter.

The grave of a previously unknown Canadian soldier has been identified as a man from Hayfield, Man. who fought in the First World War.

A group of classic car enthusiasts donated hundreds of blankets to nursing homes in Nova Scotia.

Moving into the second week of October, the eastern half of Canada can expect some brisker fall air to break down from the north

What does New Westminster's t蓹m蓹sew虛tx史 Aquatic and Community Centre have in common with a historic 68,000-seat stadium in Beijing, an NFL stadium and the aquatics venue for the Paris Olympics? They've all been named among the world's most beautiful sports venues for 2024.

The last living member of the legendary Vancouver Asahi baseball team, Kaye Kaminishi, died on Saturday, Sept. 28, surrounded by family. He was 102 years old.

New data from Greater Vancouver and the Fraser Valley shows a surge in supply and drop in demand in the region's historically hot real estate market.